OVERVIEW
Company Description
At Niowave, we understand the weight of what we do. Every isotope delivered supports a therapy already in motion, and depends on a supply that is consistent, controlled, and reliable.
Our responsibility and mission is to meet this need. Not only through production, but across the systems needed to maintain quality, build scale, and ensure delivery.
We are building the infrastructure that patients and next-generation therapies depend on. From Actinium-225 to emerging isotopes, our work will scale to support where oncology therapies are heading.
Boilerplate Statement
Founded in 2005 by Dr. Terry Grimm and headquartered in Lansing, Michigan, Niowave, Inc. is a medical radioisotope manufacturer that uses proprietary superconducting linear accelerator technology to produce critical isotopes for the development of targeted cancer therapies. Building on technology originally developed through research at U.S. national laboratories, the company designs, builds, and operates its own linear accelerators and has developed the radiochemistry infrastructure required for isotope production. Niowave produces isotopes, including Actinium-225, which is used in the development of targeted alpha therapies for cancer, and works with pharmaceutical companies and research institutions to support a reliable domestic supply of critical radioisotopes. Through its work, Niowave helps expand the availability of medical isotopes needed to advance the future of nuclear medicine. For more information, please visit www.niowaveinc.com.
Quick Facts
- Founded in 2005, Lansing, MI
- Spinout company of Michigan State University’s National Superconducting Cyclotron Laboratory
- Developed proprietary superconducting accelerator platform
- Operates proprietary cGMP isotope manufacturing facility
- Advanced manufacturing of linac equipment and hot cells regulated by State of Michigan, Nuclear Regulatory Commission, and FDA
- Produce isotopes like Actinium 225 (Ac-225) & Yttrium-90 (Y-90)
- Actinium 225 is a radioisotope used in targeted alpha therapies
- Yttrium-90 is widely used in liver cancer treatments where localized beta radiation enables precise tumor targeting
- By expanding production of Actinium-225, Niowave is helping enable the next generation of precision cancer therapies while strengthening America’s domestic medical isotope manufacturing capabilities.
New Facility Facts and Stats
In May 2026, Niowave began construction of its new $75 million production facility in Lansing, Michigan, to expand production of Actinium-225, a critical isotope used by pharmaceutical companies developing next-generation targeted cancer therapies. The new facility will significantly increase Niowave’s ability to supply Actinium-225, an essential ingredient used in precision cancer medicines currently being advanced by leading pharmaceutical companies worldwide.
- Project Investment: $85 million
- Location: Lansing, Michigan
- New jobs created: Approximately 73 highly skilled positions
- Facility Purpose: cGMP production of medical radioisotopes
- Operational target: 2028
- CM and A&E Partners: The Christman Company and Colliers Engineering & Design
Image Resources
